Article Sidebar
Published:
Jun 2, 2017DOI:
10.4314/tjpr.v16i5.4Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Antihyperglycaemic and hypolipidemic effect of methanol extracts of <i>Ageratum conyzoides</i> L (Asteraceae) in normal and diabetic rats
Abstract
Purpose: To investigate the antihyperglycaemic and hypolipidemic potential of the methanol extracts of leaf, stem and root of Ageratum conyzoides in streptozotocin (STZ)-induced diabetic rats.
Methods: The extract of each of the plant part was obtained by extraction in methanol. A total of 60 male Wistar albino rats (30 induced with diabetes and 30 normoglycaemic) were assigned into diabetic and normoglycaemic groups of 6 rats each. Methanol extracts of leaf, stem and root of Ageratum conyzoides were administered orally at a dose of 100 mg/kg to the rats for a period of 14 days, with glibenclamide as the standard drug (1 mg/kg). Fasting blood glucose and lipid profile were determined to ascertain the antihyperglycaemic and hypolipidemic activities of the different parts of the plant.
Results: Ageratum conyzoides significantly (p < 0.05) reduced fasting blood glucose (FBG) levels in diabetic rats by 38.71 ± 19.41 % (leaf), 25.64 ± 20.53 % (stem), and 34.76 ± 18.03 % (root) on day 14 of the treatment, compared with untreated diabetic rats where FBG increased by 11.33±8.91 %. Total cholesterol (leaf, 119.10 ± 8.12 mg/dl; stem, 109.28 ± 8.13 mg/dl) and triglycerides (leaf, 61.71 ± 9.37 mg/dl; stem, 72.45 ± 3.39 mg/dl) levels were also significantly (p < 0.05) lowered in diabetic rats. Low density lipoprotein cholesterol (leaf, 77.21 ± 8.12 mg/dl; stem, 64.76 ± 8.04 mg/dl; root, 79.08 ± 10.61mg/dl) levels were significantly (p < 0.05) lowered in all treated diabetic groups compared with the untreated diabetic rats (103.19 ± 6.08 mg/dl).
Conclusion: The results from this study indicate that Ageratum conyzoides has hypoglycaemic and hypolipidemic properties in rats, and this probably justifies its reported use in the traditional management of diabetes mellitus.
Keywords: Ageratum conyzoides, Diabetes mellitus, Antihyperglycaemic, Hypolipidemic
